Understanding Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)

In 2021, concerns arose regarding a rare but serious side effect associated with the AstraZeneca and Johnson & Johnson COVID-19 vaccines: vaccine-induced immune thrombotic thrombocytopenia (VITT). This condition was linked to 60 cases in the United States from nearly 19 million doses of the Johnson & Johnson vaccine, resulting in nine fatalities. Similarly, the AstraZeneca vaccine was associated with 455 cases and 81 deaths in the United Kingdom, and at least 71 cases in Germany. Following these alarming reports, both vaccines were paused and eventually withdrawn from the market. Recent research has shed light on the mechanisms behind VITT, potentially paving the way for safer vaccine designs in the future.

(The) Atlantic

A study led by Andreas Greinacher at the University of Greifswald has provided significant insights into the underlying causes of VITT. Researchers analyzed blood samples from 21 patients with VITT and discovered that a specific subset of antibodies could bind to both a portion of the adenovirus used in the vaccines and to PF4, a molecule involved in blood clotting. Notably, individuals without adverse reactions had similar antibodies but lacked the cross-reactivity with PF4. The study identified that patients with VITT possessed certain DNA variants that predisposed them to this immune overreaction. However, these genetic factors alone were insufficient; an additional mutation in immune cells was necessary for the production of the harmful antibodies.

(The) Atlantic

The findings from Greinacher's research are poised to influence the future of vaccine development, particularly in the realm of precision vaccinology, which aims to tailor vaccines to individual genetic traits. Joanne Reed, director of the Centre for Immunology and Allergy Research, emphasized that these results could lead to safer adenovirus-based vaccines by engineering around the specific protein regions that trigger VITT. Joann Arce from Boston Children’s Hospital noted that rather than discarding an entire vaccine platform due to rare complications, scientists can refine the design to mitigate risks.

(The) Atlantic

Despite the advancements in understanding VITT, questions remain regarding the complete mechanisms of clotting associated with adenovirus vaccines. Previous studies have suggested alternative pathways that may also contribute to this phenomenon. Furthermore, the research highlights the need for ongoing investigations into why infections can similarly provoke dangerous blood clotting. As understanding of these immune responses improves, it may enhance public confidence in vaccines, which are crucial for managing future pandemics, especially in low- and middle-income countries.

(The) Atlantic

• “Instead of abandoning an entire vaccine platform because of a rare problem, we can engineer around the specific issue, and that’s the power of this kind of science,” — Joann Arce, Precision Vaccines Program, Boston Children’s Hospital

(The) Atlantic

• “Arnold Lining Ju, a biomedical engineer at the University of Sydney who has studied blood clotting, told me that the paper was a landmark finding in part because of how elegantly it explains the way a specific genetic trait, combined with a particular chance mutation in certain cells, creates VITT.” — Arnold Lining Ju, Biomedical Engineer, University of Sydney

(The) Atlantic

• “Greinacher told me that adenovirus-based vaccines remain vital, including for the development of vaccines for diseases that affect mostly low- and middle-income countries.” — Andreas Greinacher, University of Greifswald

(The) Atlantic

While the recent study provides substantial evidence regarding the genetic predisposition to VITT, it does not fully resolve the question of why adenovirus-based vaccines cause clotting. Additional research is needed to explore other potential mechanisms and the relationship between infections and blood clotting events.

(The) Atlantic